CNTG: Centogene Price to Sales

Growing demand for the monetization of genetic archives allows Centogene N.V. (CNTG) to scale profits without conducting new tests. The price-to-sales ratio reflects asset overheating, where the value of 0.20 determines the parameter's status. The strategy bets on a unique DNA biobank that creates a barrier to entry for competitors and the delivery of diagnostic solutions to pharmaceutical companies, which offsets previous capital restructuring costs.

A critical decline in revenues from rare pathology diagnostics and the high cost of maintaining laboratories at Centogene N.V. (CNTG) call the business's sustainability into question. By analyzing the price-to-sales ratio, an investor can see the relationship between market capitalization and annual turnover, which allows for an assessment of the value of each unit of revenue and determines whether the current price represents an overvalued asset or an undervalued instrument.